These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 8458600)
21. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. Jacobson I; Carlsson L; Duker G J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633 [TBL] [Abstract][Full Text] [Related]
22. Mechanism-specific antiarrhythmic effects of the potassium channel activator levcromakalim against repolarization-dependent tachycardias. Vos MA; Gorgels AP; Lipcsei GC; De Groot SH; Leunissen JD; Wellens HJ J Cardiovasc Electrophysiol; 1994 Sep; 5(9):731-42. PubMed ID: 7827712 [TBL] [Abstract][Full Text] [Related]
23. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes. Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528 [TBL] [Abstract][Full Text] [Related]
24. Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart. Han C; Pogwizd SM; Killingsworth CR; Zhou Z; He B Heart Rhythm; 2013 Oct; 10(10):1509-15. PubMed ID: 23773986 [TBL] [Abstract][Full Text] [Related]
25. Antiarrhythmic drugs and torsade de pointes. Lazzara R Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758 [TBL] [Abstract][Full Text] [Related]
26. The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart. Verduyn SC; Vos MA; Gorgels AP; van der Zande J; Leunissen JD; Wellens HJ J Cardiovasc Electrophysiol; 1995 Mar; 6(3):189-200. PubMed ID: 7620644 [TBL] [Abstract][Full Text] [Related]
27. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111 [TBL] [Abstract][Full Text] [Related]
28. Terminology of torsades de pointes. Tzivoni D; Keren A; Banai S; Stern S Cardiovasc Drugs Ther; 1991 Apr; 5(2):505-7. PubMed ID: 1854659 [TBL] [Abstract][Full Text] [Related]
29. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738 [TBL] [Abstract][Full Text] [Related]
30. Early afterdepolarization in a patient with complete atrioventricular block and torsades de pointes. Kurita T; Ohe T; Shimizu W; Hotta D; Shimomura K Pacing Clin Electrophysiol; 1993 Jan; 16(1 Pt 1):33-8. PubMed ID: 7681173 [TBL] [Abstract][Full Text] [Related]
31. Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes. Kurita T; Ohe T; Shimizu W; Suyama K; Aihara N; Takaki H; Kamakura S; Shimomura K Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 1):695-705. PubMed ID: 9080496 [TBL] [Abstract][Full Text] [Related]
32. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model. Lu HR; Gallacher DJ; Yan GX J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776 [TBL] [Abstract][Full Text] [Related]
33. Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. Fabritz L; Kirchhof P; Franz MR; Eckardt L; Mönnig G; Milberg P; Breithardt G; Haverkamp W Basic Res Cardiol; 2003 Feb; 98(1):25-32. PubMed ID: 12494266 [TBL] [Abstract][Full Text] [Related]
34. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427 [TBL] [Abstract][Full Text] [Related]
35. Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model. Varkevisser R; van der Heyden MA; Tieland RG; Beekman JD; Vos MA Eur J Pharmacol; 2013 Nov; 720(1-3):49-54. PubMed ID: 24211677 [TBL] [Abstract][Full Text] [Related]
36. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Arbel Y; Swartzon M; Justo D Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403 [TBL] [Abstract][Full Text] [Related]
37. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949 [TBL] [Abstract][Full Text] [Related]
38. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. Buchanan LV; Kabell G; Brunden MN; Gibson JK J Cardiovasc Pharmacol; 1993 Oct; 22(4):540-9. PubMed ID: 7505355 [TBL] [Abstract][Full Text] [Related]
39. Comparison of sensitivity of surrogate markers of drug-induced torsades de pointes in canine hearts. Chiba K; Sugiyama A; Takasuna K; Hashimoto K Eur J Pharmacol; 2004 Oct; 502(1-2):117-22. PubMed ID: 15464097 [TBL] [Abstract][Full Text] [Related]
40. Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart. Asano Y; Davidenko JM; Baxter WT; Gray RA; Jalife J J Am Coll Cardiol; 1997 Mar; 29(4):831-42. PubMed ID: 9091531 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]